{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T05:32:37Z","timestamp":1765949557870,"version":"3.48.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Taipei Medical University and Wan Fang Hospital","award":["112TMU-WFH-10"],"award-info":[{"award-number":["112TMU-WFH-10"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00520-025-10171-y","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T20:51:43Z","timestamp":1763671903000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mannitol for prevention of cisplatin-induced nephrotoxicity: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"33","author":[{"given":"Chih-Chin","family":"Kao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiu-Yu","family":"Tai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueh-Chu","family":"Sio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yen-Chung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tu T.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6722-1153","authenticated-orcid":false,"given":"Tsai-Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"issue":"7","key":"10171_CR1","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.2215\/CJN.08070715","volume":"11","author":"S Latcha","year":"2016","unstructured":"Latcha S, Jaimes EA, Patil S et al (2016) Long-term renal outcomes after cisplatin treatment. Clin J Am Soc Nephrol 11(7):1173\u20131179. https:\/\/doi.org\/10.2215\/CJN.08070715","journal-title":"Clin J Am Soc Nephrol"},{"key":"10171_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41581-022-00631-7","volume":"19","author":"C Tang","year":"2023","unstructured":"Tang C, Livingston MJ, Safirstein R, Dong Z (2023) Cisplatin nephrotoxicity: new insights and therapeutic implications. Nat Rev Nephrol 19:53\u201372","journal-title":"Nat Rev Nephrol"},{"key":"10171_CR3","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1038\/s41401-021-00620-9","volume":"42","author":"C-Y Fang","year":"2021","unstructured":"Fang C-Y, Lou D-Y, Zhou L-Q et al (2021) Natural products: potential treatments for cisplatin-induced nephrotoxicity. Acta Pharmacol Sin 42:1951\u20131969. https:\/\/doi.org\/10.1038\/s41401-021-00620-9","journal-title":"Acta Pharmacol Sin"},{"key":"10171_CR4","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1200\/JCO.1996.14.7.2101","volume":"14","author":"G Kemp","year":"1996","unstructured":"Kemp G, Rose P, Lurain J et al (1996) Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14:2101\u20132112. https:\/\/doi.org\/10.1200\/JCO.1996.14.7.2101","journal-title":"J Clin Oncol"},{"key":"10171_CR5","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/(sici)1097-0215(19991210)83:6<866::aid-ijc34>3.0.co;2-9","volume":"83","author":"JT Hartmann","year":"1999","unstructured":"Hartmann JT, Kollmannsberger C, Kanz L, Bokemeyer C (1999) Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer 83:866\u2013869. https:\/\/doi.org\/10.1002\/(sici)1097-0215(19991210)83:6%3c866::aid-ijc34%3e3.0.co;2-9","journal-title":"Int J Cancer"},{"key":"10171_CR6","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1634\/theoncologist.2016-0319","volume":"22","author":"DJ Crona","year":"2017","unstructured":"Crona DJ, Faso A, Nishijima TF et al (2017) A systematic review of strategies to prevent cisplatin-induced nephrotoxicity. Oncologist 22:609\u2013619. https:\/\/doi.org\/10.1634\/theoncologist.2016-0319","journal-title":"Oncologist"},{"key":"10171_CR7","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1007\/S40265-019-01182-1","volume":"79","author":"A Hamroun","year":"2019","unstructured":"Hamroun A, Lenain R, Bigna JJ et al (2019) Prevention of cisplatin-induced acute kidney injury: a systematic review and meta-analysis. Drugs 79:1567\u20131582. https:\/\/doi.org\/10.1007\/S40265-019-01182-1","journal-title":"Drugs"},{"key":"10171_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/S00228-019-02771-5","volume":"76","author":"AG Casanova","year":"2020","unstructured":"Casanova AG, Hern\u00e1ndez-S\u00e1nchez MT, L\u00f3pez-Hern\u00e1ndez FJ et al (2020) Systematic review and meta-analysis of the efficacy of clinically tested protectants of cisplatin nephrotoxicity. Eur J Clin Pharmacol 76:23\u201333. https:\/\/doi.org\/10.1007\/S00228-019-02771-5","journal-title":"Eur J Clin Pharmacol"},{"key":"10171_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1159\/000510384","volume":"99","author":"T Miyoshi","year":"2021","unstructured":"Miyoshi T, Uoi M, Omura F et al (2021) Risk factors for Cisplatin-induced nephrotoxicity: a multicenter retrospective study. Oncology 99:105\u2013113. https:\/\/doi.org\/10.1159\/000510384","journal-title":"Oncology"},{"key":"10171_CR10","doi-asserted-by":"publisher","DOI":"10.1200\/go.21.00275","author":"P Sainamthip","year":"2022","unstructured":"Sainamthip P, Saichaemchan S, Satirapoj B, Prasongsook N (2022) The effect of intravenous mannitol combined with normal saline in preventing cisplatin-induced nephrotoxicity: a randomized, double-blind, placebo-controlled trial. JCO Glob Oncol. https:\/\/doi.org\/10.1200\/go.21.00275","journal-title":"JCO Glob Oncol"},{"key":"10171_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/S12885-022-09456-W","author":"A Rachman","year":"2022","unstructured":"Rachman A, Wafa S, Nugroho P, Koesnoe S (2022) The effect of mannitol addition to hydration on acute kidney injury event after high dose cisplatin chemotherapy: an ambispective cohort study. BMC Cancer. https:\/\/doi.org\/10.1186\/S12885-022-09456-W","journal-title":"BMC Cancer"},{"key":"10171_CR12","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372. https:\/\/doi.org\/10.1136\/BMJ.N71","DOI":"10.1136\/BMJ.N71"},{"key":"10171_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/S00280-003-0620-1","volume":"52","author":"JT Santoso","year":"2003","unstructured":"Santoso JT, Lucci JA, Coleman RL et al (2003) Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol 52:13\u201318. https:\/\/doi.org\/10.1007\/S00280-003-0620-1","journal-title":"Cancer Chemother Pharmacol"},{"key":"10171_CR14","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1007\/s11096-018-0677-x","volume":"40","author":"M El Hamamsy","year":"2018","unstructured":"El Hamamsy M, Kamal N, Bazan NS, El Haddad M (2018) Evaluation of the effect of acetazolamide versus mannitol on cisplatin-induced nephrotoxicity, a pilot study. Int J Clin Pharm 40:1539\u20131547. https:\/\/doi.org\/10.1007\/s11096-018-0677-x","journal-title":"Int J Clin Pharm"},{"key":"10171_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6839","volume":"13","author":"E Murakami","year":"2024","unstructured":"Murakami E, Akamatsu H, Teraoka S et al (2024) Mannitol versus furosemide in patients with thoracic malignancies who received cisplatin-based chemotherapy using short hydration: a randomized phase II trial. Cancer Med 13:e6839. https:\/\/doi.org\/10.1002\/cam4.6839","journal-title":"Cancer Med"},{"key":"10171_CR16","first-page":"31","volume":"66","author":"M Al-Sarraf","year":"1982","unstructured":"Al-Sarraf M, Fletcher W, Oishi N et al (1982) Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study. Cancer Treat Rep 66:31\u201335","journal-title":"Cancer Treat Rep"},{"key":"10171_CR17","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al (2019) RoB 2: A revised tool for assessing risk of bias in randomised trials. The BMJ 366. https:\/\/doi.org\/10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"key":"10171_CR18","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1200\/JCO.1986.4.11.1670","volume":"4","author":"IW Dimery","year":"1986","unstructured":"Dimery IW, Legha SS (1986) Sequential methotrexate, 5-fluorouracil, and cisplatin in the treatment of recurrent squamous-cell carcinoma of the head and neck: failure of hypertonic saline to reduce the nephrotoxicity of cisplatin. J Clin Oncol 4:1670\u20131676. https:\/\/doi.org\/10.1200\/JCO.1986.4.11.1670","journal-title":"J Clin Oncol"},{"key":"10171_CR19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/ajco.13423","volume":"17","author":"G Makimoto","year":"2021","unstructured":"Makimoto G, Hotta K, Oze I et al (2021) Randomized study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in non-small cell lung cancer: the OLCSG1406 trial. Asia Pac J Clin Oncol 17:101\u2013108. https:\/\/doi.org\/10.1111\/ajco.13423","journal-title":"Asia Pac J Clin Oncol"},{"key":"10171_CR20","first-page":"73","volume":"65","author":"S Ostrow","year":"1981","unstructured":"Ostrow S, Egorin MJ, Hahn D et al (1981) High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity. Cancer Treat Rep 65:73\u201378","journal-title":"Cancer Treat Rep"},{"key":"10171_CR21","first-page":"2085","volume":"25","author":"H Yoshizawa","year":"1998","unstructured":"Yoshizawa H, Suzuki E, Arakawa M (1998) Early phase II study of FK352 in cisplatin-induced nephropathy. Niigata Prefecture FK352 study group. Gan To Kagaku Ryoho 25:2085\u20132094","journal-title":"Gan To Kagaku Ryoho"},{"key":"10171_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40620-017-0392-z","volume":"31","author":"S Manohar","year":"2018","unstructured":"Manohar S, Leung N (2018) Cisplatin nephrotoxicity: a review of the literature. J Nephrol 31:15\u201325","journal-title":"J Nephrol"},{"key":"10171_CR23","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/phar.2500","volume":"41","author":"CV Burns","year":"2021","unstructured":"Burns CV, Edwin SB, Szpunar S, Forman J (2021) Cisplatin-induced nephrotoxicity in an outpatient setting. Pharmacotherapy 41:184\u2013190. https:\/\/doi.org\/10.1002\/phar.2500","journal-title":"Pharmacotherapy"},{"key":"10171_CR24","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.7314\/APJCP.2015.16.3.1117","volume":"16","author":"Y Prasaja","year":"2015","unstructured":"Prasaja Y, Sutandyo N, Andrajati R (2015) Incidence of cisplatin-induced nephrotoxicity and associated factors among cancer patients in Indonesia. Asian Pac J Cancer Prev 16:1117\u20131122. https:\/\/doi.org\/10.7314\/APJCP.2015.16.3.1117","journal-title":"Asian Pac J Cancer Prev"},{"key":"10171_CR25","doi-asserted-by":"publisher","unstructured":"Loh JM, Tran AL, Ji L, et al (2017) Baseline glomerular filtration rate and cisplatin- induced renal toxicity in urothelial cancer patients. Clin Genitourin Cancer 16:S1558\u20137673(17)30271\u20139. https:\/\/doi.org\/10.1016\/J.CLGC.2017.08.016","DOI":"10.1016\/J.CLGC.2017.08.016"},{"key":"10171_CR26","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.3390\/toxins2112490","volume":"2","author":"RP Miller","year":"2010","unstructured":"Miller RP, Tadagavadi RK, Ramesh G, Reeves WB (2010) Mechanisms of cisplatin nephrotoxicity. Toxins (Basel) 2:2490\u20132518","journal-title":"Toxins (Basel)"},{"key":"10171_CR27","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/MAJ.0b013e31812dfe1e","volume":"334","author":"X Yao","year":"2007","unstructured":"Yao X, Panichpisal K, Kurtzman N, Nugent K (2007) Cisplatin nephrotoxicity: a review. Am J Med Sci 334:115\u2013124","journal-title":"Am J Med Sci"},{"key":"10171_CR28","doi-asserted-by":"publisher","first-page":"107","DOI":"10.18632\/oncotarget.439","volume":"3","author":"N Pabla","year":"2012","unstructured":"Pabla N, Dong Z (2012) Curtailing side effects in chemotherapy: a tale of PKC\u03b4 in cisplatin treatment. Oncotarget 3:107\u2013111. https:\/\/doi.org\/10.18632\/oncotarget.439","journal-title":"Oncotarget"},{"key":"10171_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12929-019-0518-9","volume":"26","author":"V Volarevic","year":"2019","unstructured":"Volarevic V, Djokovic B, Jankovic MG et al (2019) Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity. J Biomed Sci 26:25","journal-title":"J Biomed Sci"},{"key":"10171_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.804685","author":"S Li","year":"2021","unstructured":"Li S, He X, Ruan L et al (2021) Protective effect of Mannitol on Cisplatin-induced nephrotoxicity: a systematic review and meta-analysis. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2021.804685","journal-title":"Front Oncol"},{"key":"10171_CR31","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/ics.12386","volume":"39","author":"P Andr\u00e9","year":"2017","unstructured":"Andr\u00e9 P, Villain F (2017) Free radical scavenging properties of mannitol and its role as a constituent of hyaluronic acid fillers: a literature review. Int J Cosmet Sci 39:355\u2013360","journal-title":"Int J Cosmet Sci"},{"key":"10171_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2024.106939","volume":"203","author":"EA Elmorsy","year":"2024","unstructured":"Elmorsy EA, Saber S, Hamad RS et al (2024) Advances in understanding cisplatin-induced toxicity: molecular mechanisms and protective strategies. Eur J Pharm Sci 203:106939","journal-title":"Eur J Pharm Sci"},{"key":"10171_CR33","doi-asserted-by":"publisher","first-page":"R159","DOI":"10.1186\/cc11480","volume":"16","author":"G Bragadottir","year":"2012","unstructured":"Bragadottir G, Redfors B, Ricksten SE (2012) Mannitol increases renal blood flow and maintains filtration fraction and oxygenation in postoperative acute kidney injury: a prospective interventional study. Crit Care 16:R159. https:\/\/doi.org\/10.1186\/cc11480","journal-title":"Crit Care"},{"key":"10171_CR34","doi-asserted-by":"publisher","first-page":"E173","DOI":"10.1093\/oncolo\/oyad297","volume":"29","author":"C Sikking","year":"2024","unstructured":"Sikking C, Niggebrugge-Mentink KL, van der Sman ASE et al (2024) Hydration methods for Cisplatin containing chemotherapy: a systematic review. Oncologist 29:E173\u2013E186","journal-title":"Oncologist"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-10171-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-10171-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-10171-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T05:31:22Z","timestamp":1765949482000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-10171-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10171"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-10171-y","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"assertion":[{"value":"13 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have consented to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publication consent"}},{"value":"This systematic review summarizes previously published data and does not include new human or tissue data that require ethical approval and consent. The authors assume that the studies reviewed received ethical approval and participant consent in accordance with the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1102"}}